World's Best Scientists 2026 revealed!
Kevan C. Herold

Kevan C. Herold

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Immunology 99 749 687 425 383 356 36621
Medicine 99 8577 8058 4418 4087 368 37046

Kevan C. Herold publications per year

The chart shows the history of publications by Kevan C. Herold between 1983 and 2026, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Kevan C. Herold published across 44 years, from 1983 to 2026, averaging 10.1 papers a year. Output peaked at 33 publications in 2023. 30 of the 445 publications appeared in the last two years.

No. of publications
10 20 30
Bar chart. Horizontal axis: year, 1983 to 2026. Vertical axis: number of publications, 0 to 33. Peak 33 publications in 2023. 1983: 2 publications 1984: 4 publications 1985: 1 publication 1986: 7 publications 1987: 3 publications 1988: 1 publication 1989: 2 publications 1990: 2 publications 1991: 1 publication 1992: 5 publications 1993: 2 publications 1994: 3 publications 1995: 5 publications 1996: 2 publications 1997: 4 publications 1998: 4 publications 1999: 1 publication 2000: 2 publications 2001: 1 publication 2002: 3 publications 2003: 3 publications 2004: 11 publications 2005: 13 publications 2006: 18 publications 2007: 14 publications 2008: 10 publications 2009: 11 publications 2010: 8 publications 2011: 15 publications 2012: 14 publications 2013: 23 publications 2014: 18 publications 2015: 12 publications 2016: 16 publications 2017: 11 publications 2018: 14 publications 2019: 25 publications 2020: 25 publications 2021: 17 publications 2022: 25 publications 2023: 33 publications 2024: 24 publications 2025: 29 publications 2026: 1 publication
1983 2026

445 publications in total across all disciplines

View publications per year as a table
Kevan C. Herold: publications per year, 1983 to 2026
Year Publications
1983 2
1984 4
1985 1
1986 7
1987 3
1988 1
1989 2
1990 2
1991 1
1992 5
1993 2
1994 3
1995 5
1996 2
1997 4
1998 4
1999 1
2000 2
2001 1
2002 3
2003 3
2004 11
2005 13
2006 18
2007 14
2008 10
2009 11
2010 8
2011 15
2012 14
2013 23
2014 18
2015 12
2016 16
2017 11
2018 14
2019 25
2020 25
2021 17
2022 25
2023 33
2024 24
2025 29
2026 1
Total 445
Download as CSV

Kevan C. Herold publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Kevan C. Herold sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 76 bars. Horizontal axis: publications, 62–71 to 807+. Vertical axis: number of scientists, 0 to 189. Most scientists, 189, have 152–161 publications. The last bar groups every scientist with 807 publications or more. The highlighted bar, 352–361 publications, is where this scientist sits. 62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientist 807+ publications: 100 scientists
62–71 publications 807+

This scientist: 356 publications — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

View publications distribution as a table
Number of Immunology scientists by publication count, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
Publications Scientists This scientist
62–71 9
72–81 23
82–91 40
92–101 72
102–111 86
112–121 108
122–131 150
132–141 160
142–151 159
152–161 189
162–171 166
172–181 181
182–191 188
192–201 187
202–211 178
212–221 158
222–231 168
232–241 159
242–251 160
252–261 148
262–271 116
272–281 125
282–291 115
292–301 111
302–311 95
312–321 97
322–331 97
332–341 99
342–351 96
352–361 69 356
362–371 76
372–381 71
382–391 71
392–401 62
402–411 54
412–421 41
422–431 63
432–441 53
442–451 31
452–461 42
462–471 40
472–481 29
482–491 34
492–501 30
502–511 23
512–521 41
522–531 29
532–541 28
542–551 16
552–561 18
562–571 18
572–581 17
582–591 17
592–601 17
602–611 19
612–621 13
622–631 12
632–641 11
642–651 16
652–661 9
662–671 5
672–681 13
682–691 12
692–701 6
702–711 6
712–721 9
722–731 9
732–741 6
742–751 11
752–761 10
762–771 7
772–781 12
782–791 7
792–801 5
802–806 1
807+ 100
Download as CSV

Kevan C. Herold D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Kevan C. Herold sits on this spectrum.

No. of scientists
50 100 150 200
Bar chart with 60 bars. Horizontal axis: D-Index, 40–41 to 157+. Vertical axis: number of scientists, 0 to 201. Most scientists, 201, have 58–59 D-Index. The last bar groups every scientist with 157 D-Index or more. The highlighted bar, 98–99 D-Index, is where this scientist sits. 40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40–41 D-Index 157+

This scientist: 99 D-Index — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

View D-Index distribution as a table
Number of Immunology scientists by D-index, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
D-Index Scientists This scientist
40–41 28
42–43 91
44–45 157
46–47 192
48–49 175
50–51 188
52–53 177
54–55 155
56–57 194
58–59 201
60–61 197
62–63 201
64–65 173
66–67 167
68–69 172
70–71 199
72–73 184
74–75 133
76–77 163
78–79 127
80–81 121
82–83 125
84–85 121
86–87 102
88–89 96
90–91 75
92–93 72
94–95 74
96–97 66
98–99 68 99
100–101 49
102–103 60
104–105 54
106–107 36
108–109 23
110–111 52
112–113 41
114–115 34
116–117 25
118–119 28
120–121 11
122–123 20
124–125 27
126–127 19
128–129 20
130–131 16
132–133 17
134–135 14
136–137 15
138–139 9
140–141 11
142–143 9
144–145 9
146–147 7
148–149 7
150–151 7
152–153 5
154–155 8
156 6
157+ 96
Download as CSV

Overview

Kevan C. Herold is affiliated with Yale University in the United States and has contributed extensively to academic research in medicine and biochemistry, genetics, and molecular biology. Their work spans various subfields, including genetics, endocrinology, diabetes and metabolism, surgery, immunology, and oncology.

Their research interests focus primarily on diabetes and associated disorders, diabetes management and research, pancreatic function and diabetes, immune cell function and interaction, cancer immunotherapy and biomarkers, diabetes treatment and management, and COVID-19 clinical research studies.

Herold has published numerous papers in several reputed scientific venues, with frequent contributions to journals such as Diabetes, Diabetes Care, The Journal of Immunology, Journal for ImmunoTherapy of Cancer, and bioRxiv (Cold Spring Harbor Laboratory).

Notable recent papers include:

  • Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients (2020, Science Translational Medicine)
  • Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals (2021, Science Translational Medicine)
  • Quantifying the effect of experimental perturbations at single-cell resolution (2021, Nature Biotechnology)
  • The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes (2021, JCI Insight)
  • Immunotherapy: Building a bridge to a cure for type 1 diabetes (2021, Science)

Frequent co-authors collaborating with Herold include:

  • Jay M. Sosenko
  • María J. Redondo
  • Emily K. Sims
  • Heba M. Ismail
  • Stephen E. Gitelman

Herold's body of work demonstrates a strong focus on diabetes-related research, evidenced by a high number of publications specifically in diabetes-focused journals. Their contributions to immunology and oncology also integrate with their medical research pursuits.

Best Publications

  • Genetics, pathogenesis and clinical interventions in type 1 diabetes

    Jeffrey A. Bluestone;Kevan Herold;George Eisenbarth

  • Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus

    Kevan C. Herold;William Hagopian;Julie A. Auger;Ena Poumian-Ruiz

  • Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association.

    Richard A. Insel;Jessica L. Dunne;Mark A. Atkinson;Jane L. Chiang

  • Type 1 diabetes immunotherapy using polyclonal regulatory T cells.

    Jeffrey A. Bluestone;Jane H. Buckner;Mark Fitch;Stephen E. Gitelman

  • Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation

    Ravichandran Ramasamy;Susan J. Vannucci;Shirley Shi Du Yan;Kevan Herold

  • An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

    Kevan C. Herold;Brian N. Bundy;S. Alice Long;Jeffrey A. Bluestone

  • Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.

    Deborah J. Lenschow;Stephen C. Ho;I Husain Sattar;Lesley Rhee

  • A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes

    Kevan C. Herold;Stephen E. Gitelman;Umesh Masharani;William Hagopian

  • Reprogramming human T cell function and specificity with non-viral genome targeting

    Theodore L. Roth;Cristina Puig-Saus;Ruby Yu;Ruby Yu;Eric Shifrut;Eric Shifrut

  • Familial Hyperinsulinism Caused by an Activating Glucokinase Mutation

    B Glaser;P Kesavan;M Heyman;E Davis

  • C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell Function: Report of an ADA Workshop, 21–22 October 2001

    Jerry P. Palmer;G. Alexander Fleming;Carla J. Greenbaum;Kevan C. Herold

  • Control of TH17 cells occurs in the small intestine.

    Enric Esplugues;Enric Esplugues;Enric Esplugues;Samuel Huber;Samuel Huber;Nicola Gagliani;Anja E. Hauser

  • Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

    Angeliki M. Stamatouli;Zoe Quandt;Ana Luisa Perdigoto;Pamela L. Clark

  • Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial.

    Nicole Sherry;William Hagopian;Johnny Ludvigsson;Sunil M Jain

  • Teplizumab (Anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders

    Kevan C. Herold;Stephen E. Gitelman;Mario R. Ehlers;Peter A. Gottlieb

  • CD28/B7 Regulation of Th1 and Th2 Subsets in the Development of Autoimmune Diabetes

    Deborah J. Lenschow;Kevan C. Herold;Lesley Rhee;Bina Patel

  • TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs

    Brygida Bisikirska;John Colgan;Jeremy Luban;Jeffrey A. Bluestone

  • Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

    Diane K Wherrett;Brian Bundy;Dorothy J Becker;Linda A DiMeglio

  • Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.

    Antoinette Moran;Brian Bundy;Dorothy J. Becker;Linda A. DiMeglio

  • Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients.

    Carl A. Pierce;Paula Preston-Hurlburt;Yile Dai;Clare Burn Aschner

  • TCR stimulation with modified anti-CD3 mAb expands CD8 + T cell population

    Brygida Bisikirska;John Colgan;Jeremy Luban;Jeffrey A. Bluestone

Frequent Co-Authors

Jeffrey A. Bluestone
Jeffrey A. Bluestone University of California, San Francisco
Carla J. Greenbaum
Carla J. Greenbaum Virginia Mason Medical Center
Jerry P. Palmer
Jerry P. Palmer University of Washington
Jay S. Skyler
Jay S. Skyler University of Miami
Mark A. Atkinson
Mark A. Atkinson University of Florida
Jeffrey P. Krischer
Jeffrey P. Krischer University of South Florida
Desmond A. Schatz
Desmond A. Schatz University of Florida
Ann Marie Schmidt
Ann Marie Schmidt New York University
Linda A. DiMeglio
Linda A. DiMeglio Indiana University
Raphael Clynes
Raphael Clynes Columbia University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in immunology often intersects with various healthcare disciplines, particularly nursing specialties focused on patient immune response and related conditions. Aspiring professionals can explore accelerated paths, such as an accelerated np program, which offers a fast-tracked approach to becoming a nurse practitioner with specialized knowledge valuable in immunology-related fields.

For those already in nursing, transitioning to acute care is a viable option with programs like an fnp to acnp bridge program online, equipping nurse practitioners with critical skills for managing complex immune system disorders. This flexibility allows for career growth in both clinical and research settings.

Financial considerations are key when selecting education pathways. Some of the cheapest online pmhnp certificate programs offer an affordable entry point, enabling learners to minimize debt while gaining credentials relevant to immunology-related mental health conditions.

Career prospects also depend on specialization. Graduates often target high-demand, well-compensated roles, reminiscent of those found in the highest paid dnp specialties, where expertise in immunology can enhance earning potential and job satisfaction.

Best Scientists Citing Kevan C. Herold

Trending Scientists

Recently Published Articles